Effort Launched to Adapt HIV/AIDS Drugs for Children

Extract

A nonprofit research and development organization has launched a new program to adapt HIV/AIDS medications for safer, more effective pediatric use.

The Drugs for Neglected Diseases initiative (DNDi), which is based in Geneva, Switzerland, announced the new effort in July. The program will build on the DNDi's work in developing and delivering new treatments for such neglected diseases as sleeping sickness, leishmaniasis, and Chagas disease.

HIV infection nearly has been eliminated in infants and children in developed countries because of effective treatment to prevent mother-to-child transmission of the virus. But the same preventive methods are not widely available in low-income countries.

First Page Preview

Figures

Tables

References

Letters

The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with
the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.

This feature is provided as a courtesy. By using it you agree that that you are requesting the material solely for personal, non-commercial use, and that it is subject to the AMA's Terms of Use. The information provided in order to email this article will not be shared, sold, traded, exchanged, or rented. Please refer to The JAMA Network's Privacy Policy for additional information.

Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.